Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly L Hayward

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Hepatology Communications|November 9, 2020
Improving Medication-Related Outcomes in Chronic Liver DiseaseKelly L Hayward, Rianne A Weersink
Australian Prescriber|July 2, 2021
Managing medicines in alcohol-associated liver disease: a practical reviewAmy L Johnson, Kelly L Hayward
Hepatology Communications|April 16, 2021
Collaboration Is Needed to Translate Pharmacology Data Into Better Health Outcomes in Chronic Liver DiseaseRianne A Weersink, Kelly L Hayward
British Journal of Clinical Pharmacology|October 14, 2015
Can paracetamol (acetaminophen) be administered to patients with liver impairment?Kelly L Hayward, Elizabeth E Powell, Katharine M Irvine, et al.
Journal of Hepatology|June 28, 2022
Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosisLucy Gracen, Kelly L Hayward, Katharine M Irvine, et al.
Hepatology Communications|September 10, 2019
ReplyKelly L Hayward, Patricia C Valery, W Neil Cottrell, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 8, 2019
Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerationsRianne A Weersink, David M Burger, Kelly L Hayward, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 31, 2022
An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary careLucy Gracen, Kelly L Hayward, Melanie Aikebuse, et al.
BMC Health Services Research|April 13, 2022
Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetesLucy Gracen, Kelly L Hayward, Melanie Aikebuse, et al.
Hepatology Communications|April 8, 2020
Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology ClinicsHarendran Elangovan, Sashen Rajagopaul, Suzanne M Williams, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Hepatology Communications|November 9, 2020
Improving Medication-Related Outcomes in Chronic Liver DiseaseKelly L Hayward, Rianne A Weersink
Australian Prescriber|July 2, 2021
Managing medicines in alcohol-associated liver disease: a practical reviewAmy L Johnson, Kelly L Hayward
Hepatology Communications|April 16, 2021
Collaboration Is Needed to Translate Pharmacology Data Into Better Health Outcomes in Chronic Liver DiseaseRianne A Weersink, Kelly L Hayward
British Journal of Clinical Pharmacology|October 14, 2015
Can paracetamol (acetaminophen) be administered to patients with liver impairment?Kelly L Hayward, Elizabeth E Powell, Katharine M Irvine, et al.
Journal of Hepatology|June 28, 2022
Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosisLucy Gracen, Kelly L Hayward, Katharine M Irvine, et al.
Hepatology Communications|September 10, 2019
ReplyKelly L Hayward, Patricia C Valery, W Neil Cottrell, et al.
Expert Opinion on Drug Metabolism & Toxicology|December 8, 2019
Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerationsRianne A Weersink, David M Burger, Kelly L Hayward, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|January 31, 2022
An exploration of barriers and facilitators to implementing a nonalcoholic fatty liver disease pathway for people with type 2 diabetes in primary careLucy Gracen, Kelly L Hayward, Melanie Aikebuse, et al.
BMC Health Services Research|April 13, 2022
Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetesLucy Gracen, Kelly L Hayward, Melanie Aikebuse, et al.
Hepatology Communications|April 8, 2020
Nonalcoholic Fatty Liver Disease: Interface Between Primary Care and Hepatology ClinicsHarendran Elangovan, Sashen Rajagopaul, Suzanne M Williams, et al.
Pageof 3